These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
139 related articles for article (PubMed ID: 11926874)
21. Severe hypersensitivity reactions following reintroduction of abacavir. AIDS Read; 2000 Sep; 10(9):525. PubMed ID: 11019447 [No Abstract] [Full Text] [Related]
22. HLA-B*5701 genetic screening prior to abacavir prescription in Georgia. Dvali N; Chkhartishvili N; Sharvadze L; Karchava M; Tsertsvadze T Georgian Med News; 2010 Dec; (189):16-20. PubMed ID: 21252404 [TBL] [Abstract][Full Text] [Related]
23. Hypersensitivity reactions in patients treated with abacavir: strategies to avoid such reactions. Kapoor S AIDS Patient Care STDS; 2008 Oct; 22(10):769. PubMed ID: 18778242 [No Abstract] [Full Text] [Related]
24. A simple screening approach to reduce B*5701-associated abacavir hypersensitivity on the basis of sequence variation in HIV reverse transcriptase. Chui CK; Brumme ZL; Brumme CJ; Yip B; Phillips EJ; Montaner JS; Harrigan PR Clin Infect Dis; 2007 Jun; 44(11):1503-8. PubMed ID: 17479950 [TBL] [Abstract][Full Text] [Related]
25. Abacavir hypersensitivity. Abel S; Paturel L; Cabié A N Engl J Med; 2008 Jun; 358(23):2515; author reply 2515-6. PubMed ID: 18536095 [No Abstract] [Full Text] [Related]
26. Use of patch testing for the diagnosis of abacavir-related hypersensitivity reaction in HIV patients. Giorgini S; Martinelli C; Tognetti L; Carocci A; Giuntini R; Mastronardi V; Torricelli F; Leoncini F; Lotti T Dermatol Ther; 2011; 24(6):591-4. PubMed ID: 22515676 [TBL] [Abstract][Full Text] [Related]
27. A study of HIV provider attitudes toward HLA-B 5701 testing in the United States. Watson ME; Patel LG; Ha B; Wannamaker P; Cuffe R; Shaefer M AIDS Patient Care STDS; 2009 Nov; 23(11):957-63. PubMed ID: 19839743 [TBL] [Abstract][Full Text] [Related]
28. Advances in HIV therapeutics: news from the 4th International AIDS Society Conference. Boyle BA; Elion R; Cohen CJ; DeJesus E; Hawkins T; Moyle GJ AIDS Read; 2007 Oct; 17(10):484-90. PubMed ID: 17990370 [No Abstract] [Full Text] [Related]
29. Incidence of abacavir hypersensitivity and its relationship with HLA-B*5701 in HIV-infected patients in Taiwan. Sun HY; Hung CC; Lin PH; Chang SF; Yang CY; Chang SY; Chang SC J Antimicrob Chemother; 2007 Sep; 60(3):599-604. PubMed ID: 17631508 [TBL] [Abstract][Full Text] [Related]
30. Abacavir warning. AIDS Patient Care STDS; 2000 Nov; 14(11):617. PubMed ID: 11155904 [No Abstract] [Full Text] [Related]
31. The pharmacogenetics of antiretroviral therapy: a review of studies to date. Quirk E; McLeod H; Powderly W Clin Infect Dis; 2004 Jul; 39(1):98-106. PubMed ID: 15206060 [TBL] [Abstract][Full Text] [Related]
32. Prevalence of HLA-B*57:01 allele in Argentinean HIV-1 infected patients. Moragas M; Belloso WH; Baquedano MS; Gutierrez MI; Bissio E; Larriba JM; Fay F; Aulicino P; Gurevich JM; Yaunguzian MF; Maldonado AC; Falistocco C; Sen L; Mangano A Tissue Antigens; 2015 Jul; 86(1):28-31. PubMed ID: 25922880 [TBL] [Abstract][Full Text] [Related]
33. The clinical implications of antiretroviral pharmacogenomics. Fox J; Boffito M; Winston A Pharmacogenomics; 2006 Jun; 7(4):587-96. PubMed ID: 16753006 [TBL] [Abstract][Full Text] [Related]
34. The convenience of flow cytometry for HLA-B*5701 screening to prevent abacavir hypersensitivity reactions. Airo P; Scarsi M; Malagoli A; Carella G; Izzo I; Carosi G; Torti C J Acquir Immune Defic Syndr; 2009 Jul; 51(3):361-2. PubMed ID: 19553774 [No Abstract] [Full Text] [Related]
35. Severe abacavir hypersensitivity reaction in a patient tested HLA-B*5701 negative. Bonta PI; Vermeulen JN; Speelman P; Prins JM AIDS; 2008 Jul; 22(12):1522-3. PubMed ID: 18614879 [No Abstract] [Full Text] [Related]
36. Cytokine profiling in abacavir hypersensitivity patients. Almeida CA; Martin AM; Nolan D; Lucas A; Cameron PU; James I; Phillips E; Mallal S Antivir Ther; 2008; 13(2):281-8. PubMed ID: 18505179 [TBL] [Abstract][Full Text] [Related]
37. 'Fine tuning' HIV therapy. Report on the 9th Conference on Retroviruses and Opportunistic Infections. Linde M Posit Living; 2002; 11(3):8-9, 16, 44. PubMed ID: 12035759 [No Abstract] [Full Text] [Related]
38. A near-fatal hypersensitivity reaction to abacavir: case report and literature review. Shapiro M; Ward KM; Stern JJ AIDS Read; 2001 Apr; 11(4):222-6. PubMed ID: 11392679 [TBL] [Abstract][Full Text] [Related]
39. Introduction of pharmacogenetic screening for the human leucocyte antigen (HLA) B*5701 variant in Polish HIV-infected patients. Parczewski M; Leszczyszyn-Pynka M; Wnuk A; Urbañska A; Fuksiñska K; Bander D; Boroñ-Kaczmarska A HIV Med; 2010 May; 11(5):345-8. PubMed ID: 20070406 [TBL] [Abstract][Full Text] [Related]
40. Frequency of HLA B*5701 allele carriers in abacavir treated-HIV infected patients and controls from northeastern Brazil. Crovella S; Biller L; Santos S; Salustiano A; Brandao L; Guimaraes R; Segat L; Lima Filho JL; Arraes LC Clinics (Sao Paulo); 2011; 66(8):1485-8. PubMed ID: 21915505 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]